Start-Up Spotlight: Distalmotion Wants To Bring Cost-Effective, Focused Alternative To Robotic Surgery Market
Switzerland-based Distalmotion hopes to make its Dexter robotic surgery the standard of care in procedures that entail precise dissection and suturing and market itself as a more cost-effective alternative to Intuitive Surgical’s da Vinci system.
You may also be interested in...
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
Surgical robotics giant Intuitive Surgical will soon face competition from Medtronic and Verb Surgical. With the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting on the way in Baltimore, MD this week, Wells Fargo analyst Larry Biegelsen offers an outlook on competitive robotic systems and the rising popularity by surgeons to use robotics systems in hernia, bariatric, cholecystectomy and colorectal procedures.
Cell and gene therapy represent a transformative advance in drug delivery and outcomes, with implications equally as important to human progress as the digital revolution that began three decades ago.In Vivo speaks with a key player in this evolving field, GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil Vanek, PhD.